ACT Capital Partners, L.P.’s TG Therapeutics TGTX Stock Holding History

ACT Capital Partners, L.P.’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.2M	Buy	+237,200	New	+$12.8M	8.59%	3

Other funds holding TGTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ACT Capital Partners, L.P.'s TGTX Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in TG Therapeutics (TGTX) in Q3 2026: 237,200 shares worth $13.2M. The stake represents 8.59% of the portfolio and ranks #3 among its holdings.

197 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

ACT Capital Partners, L.P. held 237,200 shares of TG Therapeutics worth $13.2M as of Q3 2026.
TG Therapeutics was a new ACT Capital Partners, L.P. position in Q3 2026.
TG Therapeutics made up 8.59% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #3 holding.
197 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.